Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease
The use of Ranolazine is associated with a significant odds reduction in CoI in elderly patients with IHD and multiple comorbidities. The neuroprotective effect of Ranolazine may be attributed to the improvement of anginal symptoms and consequent optimization of functional status and quality of life, advocating for a comprehensive therapeutic strategy in geriatric patient management.
Authors
- Giuseppe Armentaro (ORCID: https://orcid.org/0000-0001-9775-9715)
- Valentino Condoleo
- Sofia Miceli
- Elena Succurro (ORCID: https://orcid.org/0000-0003-2578-692X)
- Raffaele Maio (ORCID: https://orcid.org/0000-0002-7290-9470)
- Francesco Andreozzi (ORCID: https://orcid.org/0000-0001-9375-1513)
- Maria Perticone
- Alberto Panza
- Velia Cassano (ORCID: https://orcid.org/0000-0002-0793-1225)
- Carlo Alberto Pastura
- Vanessa Teresa Fiorentino
- Giandomenico Severini (ORCID: https://orcid.org/0009-0003-0136-4594)
- Angela Sciacqua (ORCID: https://orcid.org/0000-0003-1674-5317)
- Giorgio Sesti (ORCID: https://orcid.org/0000-0002-1618-7688)
- Carlo Fuoco
Institutions
- Magna Graecia University (IT)
- Accademia di Belle Arti di Catanzaro (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fphar.2025.1664988
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00